CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 17,027	$ 20,257
General and administrative	27,308	74,944
Settlement expense		21,366
Reimbursement of expenses from Relief Therapeutics		(771)
Total operating expenses	44,335	115,796
Loss from operations	(44,335)	(115,796)
Other (income) expenses:
Gain on extinguishment of debt		(121)
Interest income	(249)
Interest expense		18
Change in fair value of convertible note payable	505
Change in fair value of warrant liabilities	(255)	(1,692)
Change in fair value of Earnout Cash liability	(4,582)	(20,938)
Total other (income) expenses	(4,581)	(22,733)
Loss before tax	(39,754)	(93,063)
Net loss	(39,754)	(93,063)
Deemed dividend		(255,822)
Net loss attributable to common stockholders	$ (39,754)	$ (348,885)
Net loss per share:
Basic	$ (0.60)	$ (1.98)
Diluted	(0.60)	(1.98)
Net loss per share attributable to common stockholders:
Basic	(0.60)	(7.44)
Diluted	$ (0.60)	$ (7.44)
Weighted average common shares outstanding:
Basic	65,766,786	46,917,701
Diluted	65,766,786	46,917,701